118 related articles for article (PubMed ID: 8713783)
41. In vitro evaluation of new surface coatings for extracorporeal circulation.
Baksaas ST; Videm V; Fosse E; Karlsen H; Pedersen T; Mollnes TE; Hagve TA; Svennevig JL
Perfusion; 1999 Jan; 14(1):11-9. PubMed ID: 10074642
[TBL] [Abstract][Full Text] [Related]
42. The volatile anesthetic sevoflurane inhibits activation of neutrophil granulocytes during simulated extracorporeal circulation.
Schmid E; Krajewski S; Bachmann D; Kurz J; Wendel HP; Rosenberger P; Balkau B; Peter K; Unertl K; Straub A
Int Immunopharmacol; 2012 Oct; 14(2):202-8. PubMed ID: 22824074
[TBL] [Abstract][Full Text] [Related]
43. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery.
van der Kamp KW; van Oeveren W
Int J Artif Organs; 1993 Dec; 16(12):836-42. PubMed ID: 8175200
[TBL] [Abstract][Full Text] [Related]
44. Release of lysosomal hydrolases during simulated extracorporeal circulation.
Addonizio VP; Strauss JF; Chang LF; Fisher CA; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1982 Jul; 84(1):28-34. PubMed ID: 6806546
[TBL] [Abstract][Full Text] [Related]
45. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.
Takahashi H; Muto S; Nakazawa E; Yanagiba S; Masunaga Y; Miyata Y; Tamba K; Kusano E; Matsuo M; Matsuo T; Asano Y
Clin Nephrol; 2003 Jun; 59(6):458-62. PubMed ID: 12834179
[TBL] [Abstract][Full Text] [Related]
46. Effects of heparin-coating of cardiopulmonary bypass circuits on leukocytes during simulated extracorporeal circulation.
Borowiec J; Jaramillo A; Venge P; Nilsson L; Thelin S
Cardiovasc Surg; 1997 Dec; 5(6):568-73. PubMed ID: 9423940
[TBL] [Abstract][Full Text] [Related]
47. A baboon model for hematologic studies of cardiopulmonary bypass.
Hiramatsu Y; Gikakis N; Gorman JH; Khan MM; Hack CE; Velthuis HT; Sun L; Marcinkiewicz C; Rao AK; Niewiarowski S; Colman RW; Edmunds LH; Anderson HL
J Lab Clin Med; 1997 Oct; 130(4):412-20. PubMed ID: 9358080
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits.
Tong SD; Rolfs MR; Hsu LC
ASAIO Trans; 1990; 36(3):M654-6. PubMed ID: 2252775
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
Doucet JJ; Hoyt DB; Coimbra R; Schmid-Schönbein GW; Junger WG; Paul L W; Loomis WH; Hugli TE
J Trauma; 2004 Mar; 56(3):501-10; discussion 510-1. PubMed ID: 15128119
[TBL] [Abstract][Full Text] [Related]
50. Nitric oxide gas infusion to the oxygenator enhances the biocompatibility of heparin coated extracorporeal bypass circuits.
Hayashi Y; Sawa Y; Nishimura M; Chang JC; Amemiya A; Kagisaki K; Taketani S; Yamaguchi T; Hirata N; Ohtake S; Matsuda H
ASAIO J; 1998; 44(5):M456-61. PubMed ID: 9804472
[TBL] [Abstract][Full Text] [Related]
51. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
Kaizu K; Uriu K; Ikeda M
Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
[No Abstract] [Full Text] [Related]
52. Deleterious effects of complement activation on the lungs during extracorporeal circulation and its inhibition by FUT-175.
Miyamoto Y; Matsuda H; Kawashima Y
J Biomater Appl; 1989 Jul; 4(1):56-68. PubMed ID: 2664117
[TBL] [Abstract][Full Text] [Related]
53. Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation.
Heller W; Wendel HP
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S45-54. PubMed ID: 8180329
[TBL] [Abstract][Full Text] [Related]
54. Effects of surface-bound and intravenously administered heparin on cell-surface interactions: inflammation and coagulation.
Johnson G; Curry B; Cahalan L; Prater R; Biggerstaff J; Hussain A; Gartner M; Cahalan P
Perfusion; 2013 May; 28(3):263-71. PubMed ID: 23401339
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological inhibition of plasma coagulation and platelet activation during experimental long-term perfusion.
Skogby M; Friberg LG; Adrian K; Mellgren K
Scand Cardiovasc J; 2003 Sep; 37(4):222-8. PubMed ID: 12944211
[TBL] [Abstract][Full Text] [Related]
56. Platelet and neutrophil activation in cardiopulmonary bypass.
Colman RW
Ann Thorac Surg; 1990 Jan; 49(1):32-4. PubMed ID: 2404474
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits.
Fung M; Loubser PG; Undar A; Mueller M; Sun C; Sun WN; Vaughn WK; Fraser CD
J Thorac Cardiovasc Surg; 2001 Jul; 122(1):113-22. PubMed ID: 11436043
[TBL] [Abstract][Full Text] [Related]
58. ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation.
Yoshimura Y; Hiramatsu Y; Sato Y; Homma S; Enomoto Y; Jikuya T; Sakakibara Y
Ann Thorac Surg; 2003 Oct; 76(4):1234-9. PubMed ID: 14530017
[TBL] [Abstract][Full Text] [Related]
59. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass.
Wachtfogel YT; Harpel PC; Edmunds LH; Colman RW
Blood; 1989 Feb; 73(2):468-71. PubMed ID: 2917186
[TBL] [Abstract][Full Text] [Related]
60. Experimental results using nafamostat mesilate as anticoagulant during extracorporeal lung assist for 24 hours in dogs.
Okamoto T; Chung YK; Choi H; Terasaki H; Morioka T
Artif Organs; 1993 Jan; 17(1):30-6. PubMed ID: 8422232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
